Nisa Investment Advisors LLC Sells 925 Shares of Halozyme Therapeutics, Inc. $HALO

Nisa Investment Advisors LLC lessened its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 16.5% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,686 shares of the biopharmaceutical company’s stock after selling 925 shares during the period. Nisa Investment Advisors LLC’s holdings in Halozyme Therapeutics were worth $244,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. State of New Jersey Common Pension Fund D boosted its holdings in shares of Halozyme Therapeutics by 0.9% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 42,473 shares of the biopharmaceutical company’s stock valued at $2,209,000 after purchasing an additional 384 shares during the last quarter. Keeler Thomas Management LLC bought a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at about $983,000. AlphaQuest LLC boosted its holdings in shares of Halozyme Therapeutics by 2,933.1% during the 2nd quarter. AlphaQuest LLC now owns 5,308 shares of the biopharmaceutical company’s stock valued at $276,000 after purchasing an additional 5,133 shares during the last quarter. Asset Management One Co. Ltd. bought a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at about $98,000. Finally, First Citizens Bank & Trust Co. purchased a new position in shares of Halozyme Therapeutics in the 2nd quarter worth $436,000. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $66.20 on Tuesday. The firm has a market cap of $7.74 billion, a price-to-earnings ratio of 15.15, a PEG ratio of 0.35 and a beta of 1.16. The company’s 50 day moving average is $71.04 and its 200 day moving average is $62.61. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54. Halozyme Therapeutics, Inc. has a 52-week low of $42.01 and a 52-week high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.31. The company had revenue of $325.72 million for the quarter, compared to analyst estimates of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. Halozyme Therapeutics’s revenue was up 40.8% compared to the same quarter last year. During the same period last year, the company posted $0.91 earnings per share. On average, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 4,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $73.68, for a total transaction of $294,720.00. Following the transaction, the director directly owned 46,952 shares of the company’s stock, valued at $3,459,423.36. This trade represents a 7.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Nicole Labrosse sold 20,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total transaction of $1,514,200.00. Following the transaction, the chief financial officer directly owned 24,306 shares in the company, valued at approximately $1,840,207.26. The trade was a 45.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 108,227 shares of company stock valued at $7,779,595 over the last ninety days. 2.40% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on HALO. Wall Street Zen cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 5th. JPMorgan Chase & Co. increased their price target on shares of Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a report on Monday, October 27th. Zacks Research downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. JMP Securities raised their price objective on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a “market outperform” rating in a research note on Wednesday, August 6th. Finally, Benchmark raised their price objective on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. Four investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $73.11.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.